(Albany, United States) As per DelveInsight’s assessment, globally, the Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 110+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Atopic Dermatitis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Atopic Dermatitis NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Atopic Dermatitis pipeline treatment landscape of the report, click here @ Atopic Dermatitis Pipeline Outlook

 

Key Takeaways from the Atopic Dermatitis Pipeline Report

• DelveInsight’s Atopic Dermatitis Pipeline analysis depicts a robust space with 100+ active players working to develop 110+ pipeline treatment therapies.
• The leading Atopic Dermatitis Companies in the market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others
• Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, Topical corticosteroid, si-544, MEDI9929, Dupilumab, Midazolam, Omeprazole, KP-413 Ointment, Lebrikizumab, KHK4083, Dupilumab SAR231893, KY1005, and others.
• On June 2023, Eli Lilly and Company announced a study of phase 3 clinical trials for Baricitinib and Topical Corticosteriod. The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
• On April 2023, Eli Lilly and Company announced a study of phase 3 clinical trials for Baricitinib. The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
• On June 2023, selectION Therapeutics GmbH announced a study of phase 1 clinical trials for si-544. This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.

 

Atopic Dermatitis Overview

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’

 

To explore more information on the latest breakthroughs in the Atopic Dermatitis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

 

Atopic Dermatitis Emerging Drugs Profile

• Tapinarof: Dermavant Sciences
• Etrasimod: Pfizer
• B244: AOBiome
• Lirentelimab: Allakos Inc.
• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

 

Atopic Dermatitis Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.

 

Request a sample and discover the recent advances in Atopic Dermatitis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

 

Atopic Dermatitis Drugs and Companies

• Baricitinib: Eli Lilly and Company
• Topical corticosteroid: Incyte Corporation
• si-544: selectION Therapeutics GmbH
• MEDI9929: MedImmune LLC
• Dupilumab: Regeneron Pharmaceuticals

 

Atopic Dermatitis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Atopic Dermatitis Therapeutics Market include-

Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others

 

Dive deep into rich insights for drugs for Atopic Dermatitis Pipeline, click here for Atopic Dermatitis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

 

Scope of the Atopic Dermatitis Pipeline Report

• Coverage- Global
• Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others
• Atopic Dermatitis Pipeline Therapies- Baricitinib, Topical corticosteroid, si-544, MEDI9929, Dupilumab, Midazolam, Omeprazole, KP-413 Ointment, Lebrikizumab, KHK4083, Dupilumab SAR231893, KY1005, and others.
• Atopic Dermatitis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Atopic Dermatitis Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Atopic Dermatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tapinarof: Dermavant Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. B244: AOBiome
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EP262: Escient Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atopic Dermatitis Key Companies
21. Atopic Dermatitis Key Products
22. Atopic Dermatitis- Unmet Needs
23. Atopic Dermatitis- Market Drivers and Barriers
24. Atopic Dermatitis- Future Perspectives and Conclusion
25. Atopic Dermatitis Analyst Views
26. Atopic Dermatitis Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services